SciNeuro Pharmaceuticals and Novartis Join Forces to Tackle Alzheimer's Disease with Innovative Antibody Therapies SciNeuro partners with Novartis to advance next-generation antibody therapies aimed at treating Alzheimer's disease, paving the way for innovative solutions.

SciNeuro Pharmaceuticals and Novartis Join Forces to Tackle Alzheimer's Disease with Innovative Antibody Therapies #USA #Rockville #Alzheimer's #Novartis #SciNeuro

SciNeuro Pharmaceuticals Secures $53 Million Financing and Hires CFO for Neurodegenerative Disease Research SciNeuro Pharmaceuticals announces $53 million in financing and hiring of a new CFO to advance therapies for neurodegenerative diseases, focusing on innovation.

SciNeuro Pharmaceuticals Secures $53 Million Financing and Hires CFO for Neurodegenerative Disease Research #USA #Rockville #Neurodegenerative #financing #SciNeuro

SciNeuro Pharmaceuticals Secures $5M to Advance Innovative Parkinson's Treatment Through MJFF Grant SciNeuro Pharmaceuticals has been awarded a $5M grant from The Michael J. Fox Foundation to enhance the development of its innovative LRRK2-targeting therapeutic, SNP614, for Parkinson's disease.

SciNeuro Pharmaceuticals Secures $5M to Advance Innovative Parkinson's Treatment Through MJFF Grant #United_States #Michael_J._Fox #Rockville,_MD #LRRK2 #SciNeuro